Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Earnings Results, Beats Expectations By $0.05 EPS

Arcutis Biotherapeutics (NASDAQ:ARQT) issued its earnings results on Wednesday. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05, FiscalAI reports. The business had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%.

Here are the key takeaways from Arcutis Biotherapeutics’ conference call:

• Positive Sentiment: Q2 net product revenue rose 59% year over year to $129.9 million, driven by strong ZORYVE demand and improved gross-to-net deductions. The company raised its full-year 2026 revenue guidance to $525 million–$540 million from $480 million–$495 million.
• Positive Sentiment: ZORYVE received FDA approval for plaque psoriasis in children as young as two, while the FDA accepted the application for atopic dermatitis in infants down to three months, with a February 2027 decision expected. Management views the pediatric indications as significant unmet-need opportunities.
• Positive Sentiment: Arcutis is investing in growth through expanded dermatology, primary-care and pediatric sales teams, direct-to-consumer marketing, a virtual dermatology platform and AI-enabled prescription fulfillment tools. The company expects the dermatology expansion to support second-half 2026 growth, with primary-care and pediatric contributions beginning in 2027.
• Positive Sentiment: The company reported $15 million of net income and $12.6 million of operating cash flow in Q2, ending the quarter with $238.9 million in cash and marketable securities. Management expects positive cash flow for the remainder of 2026 while continuing to fund pipeline and commercial investments.
• Negative Sentiment: Chief Commercial Officer Todd Edwards will leave later this month to pursue other opportunities, creating a leadership transition. Arcutis appointed Rob Lisicky as interim CCO while it conducts a permanent search, although management characterized the commercial team and transition plan as strong.

Arcutis Biotherapeutics Trading Up 4.1%

Shares of ARQT stock traded up $1.07 during trading on Wednesday, hitting $27.10. 2,445,454 shares of the stock traded hands, compared to its average volume of 1,546,938. The firm has a market capitalization of $3.39 billion, a P/E ratio of -903.03 and a beta of 1.49. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.68 and a quick ratio of 2.46. The firm’s fifty day moving average price is $25.75 and its 200-day moving average price is $24.68. Arcutis Biotherapeutics has a 52-week low of $13.69 and a 52-week high of $31.77.

Analyst Ratings Changes

Several analysts recently issued reports on ARQT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Needham & Company LLC restated a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Finally, Wall Street Zen upgraded Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Arcutis Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Insider Activity at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 4,096 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.41, for a total transaction of $99,983.36. Following the completion of the transaction, the director owned 38,378 shares of the company’s stock, valued at $936,806.98. This trade represents a 9.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue-Jean Lin sold 4,946 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.38, for a total transaction of $120,583.48. Following the transaction, the director directly owned 27,567 shares of the company’s stock, valued at $672,083.46. The trade was a 15.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 10,334 shares of company stock valued at $250,697 over the last quarter. 9.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds have recently bought and sold shares of ARQT. Suvretta Capital Management LLC grew its position in Arcutis Biotherapeutics by 14.2% in the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock valued at $347,435,000 after acquiring an additional 1,486,000 shares in the last quarter. State Street Corp boosted its stake in shares of Arcutis Biotherapeutics by 18.2% in the fourth quarter. State Street Corp now owns 5,488,301 shares of the company’s stock valued at $159,380,000 after purchasing an additional 846,986 shares during the period. Polar Capital Holdings Plc boosted its stake in shares of Arcutis Biotherapeutics by 5.8% in the third quarter. Polar Capital Holdings Plc now owns 5,298,754 shares of the company’s stock valued at $99,882,000 after purchasing an additional 292,279 shares during the period. Morgan Stanley grew its holdings in shares of Arcutis Biotherapeutics by 1.5% in the fourth quarter. Morgan Stanley now owns 4,340,239 shares of the company’s stock valued at $126,041,000 after purchasing an additional 63,845 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Arcutis Biotherapeutics by 0.4% in the third quarter. UBS Group AG now owns 2,948,438 shares of the company’s stock valued at $55,578,000 after purchasing an additional 10,499 shares in the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.